RECRUITING

Fasting Insulin and HOMA-IR by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study aims to investigate the relationship between fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) across various demographic factors, including age, sex, race/ethnicity, BMI, and polycystic ovary syndrome (PCOS) diagnosis. By analyzing these variables, the study seeks to identify potential variations in insulin levels, which could provide valuable insights into the impact of different factors on metabolic health and the development of insulin-related conditions.

Official Title

Measuring Fasting Insulin and HOMA-IR by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis

Quick Facts

Study Start:2024-02-01
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05950282

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age: Participants aged 18+ years.
  2. * Sex: Both males and females.
  3. * Race/Ethnicity: Participants from diverse racial and ethnic backgrounds
  4. * BMI: Participants with a range of body mass index (BMI) values
  5. * PCOS Diagnosis: Participants with and without a confirmed diagnosis PCOS based on established diagnostic criteria.
  1. * Age: Participants below 18 years
  2. * Sex: None. Both males and females are included.
  3. * Race/Ethnicity: None. Participants from all racial and ethnic backgrounds are included.
  4. * Endocrine Disorders: Participants with other endocrine disorders affecting insulin levels, such an insulin secreting tumor.

Contacts and Locations

Study Contact

Ali M Chappell, PhD, MS, RD
CONTACT
8064417275
achappell@lillihealth.com

Principal Investigator

Ali M Chappell
PRINCIPAL_INVESTIGATOR
Lilli Health

Study Locations (Sites)

Lilli Health
Houston, Texas, 77554
United States

Collaborators and Investigators

Sponsor: Lilli Health

  • Ali M Chappell, PRINCIPAL_INVESTIGATOR, Lilli Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-01
Study Completion Date2026-12

Study Record Updates

Study Start Date2024-02-01
Study Completion Date2026-12

Terms related to this study

Keywords Provided by Researchers

  • PCOS
  • Hyperinsulinemia
  • Insulin Resistance
  • Metabolic Syndrome
  • Obesity
  • Type 2 Diabetes

Additional Relevant MeSH Terms

  • Insulin Resistance
  • Polycystic Ovary Syndrome
  • Hyperinsulinism
  • Obesity
  • Metabolic Syndrome